Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of LY3374849 in Healthy Subjects
NCT03726125Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2018
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LY3374849 in diabetes mellitus (DM) (6 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) Considered by the Investigator to be Related to Study Drug Administration at 11 weeks. Started Nov 2018; status: completed.
02
Drugs
LY3374849
03
Conditions
diabetes mellitus (DM)
Beyond the preview
Go deeper on NCT03726125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03726125.